Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2015 - 2026)
Sunshine Biopharma's (SBFM) quarterly Depreciation & Amortization (CF) came in at $76859.0 in Q1 2026, up 18.62% YoY from $64793.0 in Q1 2025, and down 22.03% on a QoQ basis from $98581.0 in Q4 2025.
Sunshine Biopharma (SBFM) Depreciation & Amortization (CF) (2015 - 2026) Analysis & Trends
Sunshine Biopharma (SBFM) has 10 years of Depreciation & Amortization (CF) data on file, last reported at $76859.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) rose 18.62% year-over-year to $76859.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $344136.0 (up 40.06% YoY) and the FY2025 annual result came in at $332070.0, up 48.56% from the prior year.
- Depreciation & Amortization (CF) fell to $76859.0 in Q1 2026, from $98581.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $98581.0 in Q4 2025 to a low of $789.0 in Q3 2022.
- A 5-year average of $47456.8 and a median of $42618.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) plunged 75.21% — and 2023, when it soared 4614.83%.
- Tracing SBFM's Depreciation & Amortization (CF) over 5 years: stood at $18977.0 in 2022, then jumped by 123.18% to $42353.0 in 2023, then jumped by 54.41% to $65399.0 in 2024, then soared by 50.74% to $98581.0 in 2025, then fell by 22.03% to $76859.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $76859.0 (Q1 2026), $98581.0 (Q4 2025), and $96163.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 241.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 24.20 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 672.30 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 171.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Sunshine Biopharma | 1.58 Mn | -12.17 Mn | 2.43 Mn | 77,974.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77,974.00 |
| Jun 30, 2026 | 77,974.00 |
| Mar 31, 2026 | 76,859.00 |
| Mar 31, 2026 | 76,859.00 |
| Dec 31, 2025 | 98,581.00 |
| Dec 31, 2025 | 98,581.00 |
| Sep 30, 2025 | 96,163.00 |
| Sep 30, 2025 | 96,163.00 |
| Jun 30, 2025 | 72,533.00 |
| Jun 30, 2025 | 72,533.00 |
| Mar 31, 2025 | 64,793.00 |
| Mar 31, 2025 | 64,793.00 |
| Dec 31, 2024 | 65,399.00 |
| Dec 31, 2024 | 65,399.00 |
| Sep 30, 2024 | 64,634.00 |
| Sep 30, 2024 | 64,634.00 |
| Jun 30, 2024 | 50,876.00 |
| Jun 30, 2024 | 50,876.00 |
| Mar 31, 2024 | 42,618.00 |
| Mar 31, 2024 | 42,618.00 |